



P4C HIV TAC Collaborative Training: Hepatitis C Virus (HCV) Treatment Guidelines

Presenter: Stacey B. Trooskin, M.D., Ph.D Director of Viral Hepatitis Programs Philadelphia FIGHT Community Health Centers Philadelphia, PA July 26, 2017





Vision | Integrity | Knowledge | Solutions

Jointly provided by Postgraduate Institute for Medicine and the MayaTech Corporation





Vision | Integrity | Knowledge | Solutions

Faculty Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

- Grant Support from Gilead Sciences, FOCUS program
- Advisory Board, Gilead Sciences (former)

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Postgraduate Institute for Medicine and the Maya Tech Corporation. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Nursing Continuing Education

Credit Designation

This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

International Association for Continuing Education and Training ® (IACET) Credits

Accreditation Statement

Postgraduate Institute for Medicine is accredited by the International Association for Continuing Education and Training (IACET) and is authorized to issue the IACET CEU.

How to Obtain Your CME/CE Certificate

PIM supports Green CME/CE by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please follow the steps below:

- 1. Direct your web browser to: <u>www.cmeuniversity.com</u> and register or login
- 2. Once logged in, click on "Find Post-test/Evaluation by Course" at the top of the page
- 3. Type in <u>course code 12667</u> in the box, and hit enter
- 4. Click on the activity title
- 5. Complete the online evaluation and obtain your CME/CE certificate immediately to download and/or print for your files.

Upon completion of the online evaluation form, you will have immediate access to a certificate of attendance to print or save for your files. You can save your certificate by selecting the "Save" option on the print screen.

For any questions relating to the certification for this activity, please contact Postgraduate Institute for Medicine at: <u>inquiries@pimed.com</u> or (303) 799-1930.





AASLD/IDSA HCV Treatment Guidelines: A Focus on the HIV/HCV Coinfected Patient

Stacey B. Trooskin, M.D., Ph.D. Director of Viral Hepatitis Programs Philadelphia FIGHT Community Health Centers Philadelphia, PA







Vision | Integrity | Knowledge | Solutions





Objectives

- Discuss the treatment guidelines recommended by the American Association for the Study of Liver Diseases (AASLD) and The Infectious Diseases Society of America (IDSA)
- Describe the main treatment options for HCV infection among HIV infected patients
- List host and viral factors that influence the duration and/or type of antiviral treatment









AASLD/IDSA Guidance

- This Guidance should be considered a "living document" and will be updated frequently
 - FDA-approved regimens
 - May also recommend off-label use of certain drugs or tests

NOTICE: Guidance for hepatitis C treatment in adults is changing constantly with the advent of new therapies and other developments. A static version of this guidance, such as printouts of this website material, booklets, slides, and other materials, may be outdated by the time you read this. We urge you to review this guidance on this website (www.hcvguidelines.org) for the latest recommendations.







AASLD/IDSA Homepage



PHILADELPHIA FIGHT COMMUNITY HEALTH CENTERS





Hepatitis C History in Review







Prevalence of HIV/HCV coinfection is high

- Shared routes of transmission
 - 30% of HIV+ are coinfected
 - ~400,000 HIV/HCV + in U.S.
- Prevalence of HCV in HIV+ individuals varies based on likely mode of acquisition
 - ~ 90% in IVDU
 - 60-85% in hemophiliacs
 - 4-8% in MSM



Sherman KE. Clin Infect Dis; 2002; 34:831–7 Rockstroh JK. J Infect Dis 2005; 192:992–1002





AntiRetroviral Therapy (A.R.T.) impact on HCV Treatment/Care



Increased morbidity and mortality related to HCV

Liver disease is the second leading cause of death in HIV Liver disease is primarily caused by chronic HCV



Sherman KE et al. *Clin Infect Dis* 2002;34:831-7 D:A:D Study. *Arch Intern Med* 2006;166:1632-41



Vision | Integrity | Knowledge | Solutions



HCV/HIV Co-infection Treatments

- decreased clearance of HCV
- increased HCV RNA levels
- increased risk of cirrhosis
- increased risk of end-stage liver disease and hepatic decompensation
- increased risk of hepatocellular carcinoma
- 30-50% of coinfected individuals have alcohol use disorders





ech[®] Corporation



ETOH



Recommendations for One-time HCV Testing

RECOMMENDED

- One-time HCV testing is recommended for persons born between 1945 and 1965, without prior ascertainment of risk.
- Other persons should be screened for risk factors for HCV infection, and onetime testing should be performed for all persons with behaviors, exposures, and conditions associated with an increased risk of HCV infection.

Risk Behaviors

- Injection-drug use (current or ever, including those who injected once)
- Intranasal illicit drug use

lech[®] Corporation

http://www.hcvguidelines.org/evaluate/testing-and-linkage





Recommendations for One-time HCV Testing (2)

Risk exposures

- Persons on long-term hemodialysis (ever)
- Persons with percutaneous/parenteral exposures in an unregulated setting
- Healthcare, emergency medical, and public safety workers after needlesticks, sharps, or mucosal exposures to HCV-infected blood
- Children born to HCV-infected women
- Prior recipients of transfusions or organ transplants, including persons who:
 - Were notified that they received blood from a donor who later tested positive for HCV infection
 - Received a transfusion of blood or blood components, or underwent an organ transplant before July 1992
 - Received clotting factor concentrates produced before 1987
- Persons who were ever incarcerated

ech[®] Corporation

http://www.hcvguidelines.org/evaluate/testing-and-linkage





Recommendations for One-time HCV Testing (3)

Other considerations

• HIV infection

ech[®] Corporation

- Sexually active persons about to start pre-exposure prophylaxis (PreP) for HIV
- Unexplained chronic liver disease and/or chronic hepatitis including elevated alanine aminotransferase levels
- Solid organ donors (deceased and living)

http://www.hcvguidelines.org/evaluate/testing-and-linkage







Recommendation for HCV Testing Those with Ongoing Risk Factors

Annual HCV testing is recommended for persons who inject drugs and for HIV-seropositive men who have unprotected sex with men. Periodic testing should be offered to other persons with ongoing risk factors for exposure to HCV.

http://www.hcvguidelines.org/evaluate/testing-and-linkage





lech[®] Corporation



Recommendations for Follow-up of Initial Testing

- An anti-HCV test is recommended for HCV testing, and if the result is positive, current infection should be confirmed by a sensitive HCV RNA test.
- Among persons with a negative anti-HCV test who are suspected of having liver disease, testing for HCV RNA or follow-up testing for HCV antibody is recommended if exposure to HCV occurred within the past six months; testing for HCV RNA can also be considered in persons who are immunocompromised.
- Among persons at risk of reinfection after previous spontaneous or treatment-related viral clearance, initial HCV-RNA testing is recommended because an anti-HCV test is expected to be positive.
- Quantitative HCV-RNA testing is recommended prior to the initiation of antiviral therapy to document the baseline level of viremia (ie, baseline viral load).
- Testing for HCV genotype is recommended to guide selection of the most appropriate antiviral regimen.
- If found to have positive results for anti-HCV test and negative results for HCV RNA by polymerase chain reaction (PCR), persons should be informed that they do not have evidence of current (active) HCV infection.

http://www.hcvguidelines.org/evaluate/testing-and-linkage



aTech[®] Corporation



HCV Testing Algorithm



https://hab.hrsa.gov/sites/default/files/hab/clinical-quality-management/hepccoinfectguide2011.pdf



ayaTech[®] Corporation



OMMUNITY HEALT

Recommendations for Counseling Those with Current (Active) HCV Infection

Persons with current (active) HCV infection should receive education and interventions aimed at reducing progression of liver disease and preventing transmission of HCV.

- 1. Abstinence from alcohol and, when appropriate, interventions to facilitate cessation of alcohol consumption should be advised for all persons with HCV infection.
- 2. Evaluation for other conditions that may accelerate liver fibrosis, including HBV and HIV infections, is recommended for all persons with HCV infection.
- 3. Evaluation for advanced fibrosis using liver biopsy, imaging, and/or noninvasive markers is recommended for all persons with HCV infection, to facilitate an appropriate decision regarding HCV treatment strategy and to determine the need for initiating additional measures for the management of cirrhosis (eg, hepatocellular carcinoma screening) (see When and in Whom to Initiate HCV Therapy).
- 4. Vaccination against hepatitis A and hepatitis B is recommended for all susceptible persons with HCV infection.
- 5. Vaccination against pneumococcal infection is recommended to all patients with cirrhosis (Marrie, 2011).
- 6. All persons with HCV infection should be provided education on how to avoid HCV transmission to others. <u>http://www.hcvguidelines.org/evaluate/testing-and-linkage</u>
 PHILADELPHIA
 AyaTech® Corporation





Additional Laboratory Testing

The following laboratory tests are recommended within 12 weeks prior to starting antiviral therapy:

- Complete blood count (CBC); international normalized ratio (INR)
- Hepatic function panel (albumin, total and direct bilirubin, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels)
- Calculated glomerular filtration rate (GFR)

The following laboratory testing is recommended at any time prior to starting antiviral therapy:

- HCV genotype and subtype
- Quantitative HCV RNA (HCV viral load)









Additional Laboratory Testing (cont)

All patients initiating HCV DAA therapy should be assessed for HBV coinfection with HBsAg, anti-HBs, and anti-HBc.

Testing for the presence of resistance-associated substitutions (RASs) prior to starting treatment should be performed

See recommendations in the Initial Treatment and the Retreatment Sections of the Guidance.

Patients scheduled to receive an HCV NS3 protease inhibitor should be assessed for a history of decompensated liver disease and for severity of liver disease using CTP score.

- CTP score of 7 or > should NOT receive treatment with NS3 protease inhibitors
- CTP score of 5 or 6, who cannot be closely monitored for laboratory or clinical symptoms during treatment, should not receive treatment with a regimen that contains paritaprevir/ritonavir.









Staging HCV Liver Fibrosis

Important part of chronic HCV work-up

Identify cirrhosis:

- Increased hepatocellular carcinoma risk: need to screen
- Monitor for hepatic decompensation
- Consider liver transplant evaluation

Determine cirrhosis by:

- Liver biopsy
- Non-invasive tests









Monitoring for HCC

Advanced fibrosis and cirrhosis

Hepatic ultrasound +/- AFP every 6 months

- Suspicious mass lesion requires more specific testing with a multi-phase contrast CT or MRI
- AFP alone is inadequate screening test for HCC

Routine screening for HCC without advanced fibrosis is not recommended









The Cirrhotic Patient

Evaluate for encephalopathy & ascites

- If ascites refer to hepatologist
 - Diagnostic paracentesis
 - Evaluation for liver transplant

Endoscopy to evaluate for the presence of esophageal varices

• need for prophylaxis with a non-selective beta blocker









Goal of Treatment

The goal of treatment of HCV-infected persons is to reduce all-cause mortality and liver-related health adverse consequences, including end-stage liver disease and hepatocellular carcinoma, by the achievement of virologic cure as evidenced by a sustained virologic response.

http://www.hcvguidelines.org/evaluate/when-whom





ech[®] Corporation





Recommendation for When and in Whom to Initiate Treatment

Treatment is recommended for all patients with chronic HCV infection, except those with short life expectancies that cannot be remediated by treating HCV, by transplantation, or by other directed therapy. Patients with short life expectancies owing to liver disease should be managed in consultation with an expert.

http://www.hcvguidelines.org/evaluate/when-whom





ech[®] Corporation



SVR rates for patients with HCV infections (genotypes 1–3) according to the treatment regimens and durations





DAA: Direct Acting Antiviral

NS3/4A Inhibitors

- High Potency
- Limited genotypic coverage
- Low barrier to resistance

NS5B Nucleos(t)ide Inhibitors (NI)

- Intermediate potency
- Pan genotypic coverage
- High barrier to resistance

NS5A Inhibitors

- High potency
- Multi-genotypic coverage

ech[®] Corporation

• Intermediate barrier to resistance

NS5B Non Nucleoside Inhibitors (NNI)

- Intermediate potency
- Limited genotypic coverage
- Low barrier to resistance







Mnemonic to Remember DAAs

Look at end of the drug's name

PREvir = **PR**ot**E**ase inhibitor

• Telaprevir, boceprevir, simeprevir, grazoprevir

Uvir = nUcleotide or non-nUcleotide polymerase inhibitor

• Sofosbuvir, dasabuvir

Asvir = NS5A inhibitor

ech[®] Corporation

• Ledipasvir, ombitasvir, daclatasvir, velpatasvir, elbasvir,







Factors Associate with Treatment and Cure

HCV Genotype

- 1, 2, 3, 4, 5, 6
- Subtype: 1a, 1b

Stage of liver fibrosis

- Cirrhosis versus no cirrhosis
- Metavir score F0-F4

HCV treatment status

• Naïve versus treatment experienced

Special populations

ech[®] Corporation

• Transplant, chronic kidney dis, children





Medications Currently FDA Approved

Medication	Genotype	Genotype	Genotype	Genotype	Genotype	Genotype
Elbasvir/grazoprevir	GT1a	1b			4	
Ledipasvir/Sofosbuvir	1a	1b			4	5/6
Paritaprevir/ritonavir/ ombitasvir/dasabuvir	1a	1b			4	
Simeprevir + sofosbuvir	1a	1b				
Sofosbuvir/velpatasvir	1a	1b	2	3	4	5/6
Daclatasvir + sofosbuvir	1a	1b	2	3		





Regimens NOT recommended for HIV/HCV coinfected patients

	Tipranavir	Cobisistat	Efavirenz	Etravirine	Nevirapine	Rilpivarine	Any PI	Other
Elb/Graz		X	X	X	X		X	
Sof/Vel	X		X	X	X			
Sof/Led	X							
PrOD*	x (r)	X	X	X	X	X		Darunavir Lopinavir (r)
Simeprevir		X	X	X	X		Х	

Antiretroviral treatment interruption to allow HCV therapy is NOT recommended

*Ombitasvir/paritaprevir/ritonavir <u>+</u> dasabuvir (PrOD) should not be used in HCV/HIV-coinfected patients who are not taking ART



AASLD and IDSA. <u>http://www.hcvguidelines.org/full-report-view</u> Version July 15, 2017.







Ribavirin Drug Interactions

Do not use zidovudine with ribavirin

- Greater decrease in hemoglobin
- Higher risk of anemia

Do <u>not</u> use didanosine with ribavirin

• Risk of mitochondrial toxicity

Vision | Integrity | Knowledge | Solutions

Do not use stavudine with ribavirin

Abacavir

- May compete intracellularly with ribavirin
- No decrease in SVR with weight-based ribavirin



Alvarez D et al. *J Viral Hepat* 2006;13:683-9 Amorosa VK et al. *Antivir Ther* 2010;15:91-9





	*probably ok **atazanavir ok † maraviroc ol						oc ok		
	Abacavir	Emtricitabine	Enfuvirtide	Lamivudine	Raltegravir	Dolutegravir	Rilpivirine	Tenofovir (TDF)	
Elb/Graz	~	~	~	~	~	~	~	~	
Sof/Vel	Can be used with most antiratrovirals								
Sof/Led									
PrOD**		~	~	~	~	~		~	
Simeprevir †	~	~	~	~	~	* 🗸	~	~	

Vel and Led increase tenofovir levels when given as TDF. Avoid in those with CrCl below 60 mL/min. Renal monitoring is recommended during the dosing period



Vision | Integrity | Knowledge | Solutions

ayaTech® Corporation

X Avoid Led+ TDF + ritonovir or cobi



Recommended Regimens for HIV/HCV-coinfected Individuals

- HIV/HCV-coinfected persons should be treated and retreated the same as persons without HIV infection, after recognizing and managing interactions with antiretroviral medications (see Initial Treatment of HCV Infection and Retreatment of Persons in Whom Prior Therapy Has Failed).
- Daily daclatasvir (refer above for dose) plus sofosbuvir (400 mg), with or without ribavirin (refer to Initial Treatment of HCV Infection and Retreatment of Persons in Whom Prior Therapy Has Failed sections for duration) is a Recommended regimen when antiretroviral regimen changes cannot be made to accommodate alternative HCV direct-acting antivirals.

http://www.hcvguidelines.org/node/662/summary





aTech® Corporation



Regimens Not Recommended for Patients with HIV/HCV Coinfection

• Treatment courses shorter than 12 weeks, such as the use of 8 weeks of ledipasvir/sofosbuvir.





Vision | Integrity | Knowledge | Solutions





Monitoring Guidance

- Clinic visits or telephone contact as clinically indicated
- CBC, Cr level, GFR, hepatic function panel after 4 weeks and as clinically indicated
- Patients receiving elbasvir/grazoprevir should be monitored with hepatic function panel at 8 weeks (and again at 12 if receiving 16 weeks treatment)
- 10 fold increase in ALT at week 4 <10 fold increase with symptoms should prompt discontinuation
- If <10 fold and no symptoms, repeat ALT at week 6 and 8



ech[®] Corporation





Monitoring Recommendations

- Quantitative HCV testing at 4 weeks of therapy and 12 weeks following completion of therapy
- Antiviral therapy should NOT be interrupted or discontinued if viral load testing is not able to be done
- Viral load testing can be considered at the end of treatment and 24 weeks or longer following completion
- Patients with compensated cirrhosis on paritaprevir/ritonavir based regimen should be monitored per guidelines
- For HBsAg+ patients who are not already on HBV suppressive therapy, monitor HBV DNA levels during and immediately after treatment and antiviral treatment should be given if criteria are met







Testing Recommendations

- If HCV RNA is detectable at week 4 of treatment, repeat quantitative HCV RNA viral load testing is recommended treatment week 6
- If quantitative HCV viral load has increased by greater than 10-fold (>1 log₁₀ IU/mL) on repeat testing at week 6 (or thereafter), then discontinuation of HCV treatment is recommended







NEXT SESSION: HIV TAC COLLABORATIVE TRAINING

Challenges in Access to HCV Care Date: Wednesday, August 23, 2017

Time: 12:00PM - 1:00 PM EDT

Register Here:

https://attendee.gotowebinar.com/register/7335664884775362305







WE NEED YOU!

Participate as Health Center co-presenter.

Contact:

Victor Ramirez,

P4C HIV TAC Collaborative Training Coordinator vramirez@mayatech.com



Vision | Integrity | Knowledge | Solutions



Thank you for participating in this Webinar.

We hope that you are able to find the information provided useful as you continue your P4C project. We ask that you take a few moments to complete the feedback survey you will receive when you close out of this webinar.

If you have any additional questions, please email us: <u>P4CHIVTAC@mayatech.com</u>

